Analysts at Mizuho initiated coverage on shares of Xencor (NASDAQ:XNCR) in a report issued on Wednesday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

A number of other analysts have also commented on the company. BidaskClub raised Xencor from a “strong sell” rating to a “sell” rating in a report on Tuesday, May 7th. Raymond James assumed coverage on Xencor in a research note on Thursday, March 14th. They issued an “outperform” rating and a $27.85 price target on the stock. Piper Jaffray Companies raised their price target on Xencor to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 26th. Berenberg Bank began coverage on Xencor in a research note on Wednesday, March 27th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Guggenheim began coverage on Xencor in a research report on Friday, April 12th. They set a “buy” rating and a $42.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. Xencor presently has a consensus rating of “Buy” and an average price target of $41.49.

XNCR stock traded up $0.32 on Wednesday, reaching $31.70. 133,141 shares of the company traded hands, compared to its average volume of 212,274. Xencor has a one year low of $27.75 and a one year high of $48.38. The company has a quick ratio of 6.66, a current ratio of 6.66 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.76 billion, a PE ratio of -24.20 and a beta of 1.30.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported $1.38 EPS for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.95. The business had revenue of $111.94 million during the quarter, compared to the consensus estimate of $60.05 million. On average, research analysts expect that Xencor will post -0.08 earnings per share for the current fiscal year.

In other news, major shareholder John S. Stafford III purchased 5,500 shares of the stock in a transaction that occurred on Monday, March 25th. The stock was purchased at an average price of $29.84 per share, for a total transaction of $164,120.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder John S. Stafford III purchased 1,100 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average price of $29.90 per share, with a total value of $32,890.00. The disclosure for this purchase can be found here. Insiders have acquired 74,152 shares of company stock worth $2,182,413 over the last three months. 4.70% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in XNCR. Marshall Wace LLP acquired a new stake in Xencor in the 1st quarter valued at approximately $797,000. Man Group plc acquired a new stake in Xencor in the 1st quarter valued at approximately $2,432,000. Goldman Sachs Group Inc. increased its holdings in Xencor by 2.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 297,655 shares of the biopharmaceutical company’s stock valued at $9,245,000 after purchasing an additional 7,590 shares during the last quarter. Geode Capital Management LLC increased its holdings in Xencor by 8.3% in the 1st quarter. Geode Capital Management LLC now owns 596,399 shares of the biopharmaceutical company’s stock valued at $18,524,000 after purchasing an additional 45,757 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Xencor by 4.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 270,989 shares of the biopharmaceutical company’s stock valued at $8,417,000 after purchasing an additional 11,980 shares during the last quarter. Institutional investors and hedge funds own 83.51% of the company’s stock.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Recommended Story: Producer Price Index (PPI)

The Fly

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.